{"entity":{"id":"nct03315754","kind":"trial","name":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.","summary":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer is a phase 2 interventional study registered as NCT03315754 by Steba Biotech S.A., with 50 participants recorded, started 2017-10-02 and reaching its primary completion in 2020-11-02. Interventions recorded: TOOKAD Soluble 4 mg/kg. Conditions recorded: Localized Prostate Cancer.\n\nLinked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03315754","url":"https://clinicaltrials.gov/study/NCT03315754"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-intermediate-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["padeliporfin"],"companies":["steba-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03315754","phase":"2","setting":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.","sponsor":"Steba Biotech S.A.","started":"2017-10-02","startedType":"actual","yearReported":2023,"enrolled":50,"enrolledBasis":"registry","outcomes":[{"endpoint":"Participants With Negative Biopsy for Gleason Score 7 (Gleason Grade 4 or 5) Prostate Cancer on 12-month Post-treatment","primary":true,"unit":"participants","arms":[{"name":"12 Months Follow up PP Group","n":44,"value":37,"note":"Figures from the ClinicalTrials.gov results section (first posted 2023-08-02), not from a publication"},{"name":"12 Months Follow up ITT Group","n":50,"value":38}],"source":"https://clinicaltrials.gov/study/NCT03315754?tab=results"}]},"route":"/trials/nct03315754/","neighbours":{"cancer":[{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/"}],"company":[{"id":"steba-biotech","kind":"company","name":"Steba Biotech","route":"/companies/steba-biotech/"}]}}